ATE — Antibe Therapeutics(Pre-Merger) Income Statement
0.000.00%
Last trade - 00:00
- CA$15.64m
- -CA$9.27m
- 24
- 46
- 14
- 18
2019 March 31st | R2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 9.54 | 9.67 | 9.71 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | 3.55 | 3.7 | 3.55 | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 21.7 | 28.3 | 34.4 | 25.5 | 20.5 |
Operating Profit | -12.2 | -18.6 | -24.7 | -25.5 | -20.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -12.7 | -19.1 | -24.7 | -25.3 | -19.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -12.8 | -19.1 | -24.7 | -25.3 | -19.3 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -12.8 | -19.3 | -26.3 | -25.1 | -19.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -12.8 | -19.3 | -26.3 | -25.1 | -19.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.606 | -0.673 | -0.691 | -0.499 | -0.369 |